PLX-4545

Overview

PLX-4545 is an orally active, selective molecular glue degrader targeting IKZF2 . Through a molecular glue mechanism, PLX-4545 binds to CRBN , recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (T reg ) into effector-like T cells, enhances CD8 + T cell responses, and modulates the T eff :T reg balance. PLX-4545 also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of T reg . PLX-4545 can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti- PD1 .

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Molecular Glues | Products > Signaling Pathways > Ligands for E3 Ligase | Products > Signaling Pathways > IKZF Family

Product Information

• Catalog No.: HY-159647
• CAS No.: 2892065-45-9
• Molecular Formula: C28H31N3O4
• Molecular Weight: 473.56
• Purity: 96.76%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.28 mM); Clear solution
• Availability: In-stock

Source

Original product source